We protect your health through science
Investigation
Arbovirus and imported viral diseases
Research projects
Content with Investigacion .
PROYECTOS VIGENTES
Título del proyecto: "Vesículas extracelulares y otras moléculas de parásitos para el tratamiento de la enfermedad inflamatoria intestinal: PARATREAT-IBD"
Referencia: Proyecto PID2022-137661OB-I00 (MPY 341/23) financiado por MCIN/AEI /10.13039/501100011033/ y por FEDER Una manera de hacer Europa
Fecha Inicio: 01/12/2023
Fecha Fin: 31/08/2026
Financiación: 162.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Agencia Estatal de Investigación. MICINN.
Título del proyecto: "Desarrollo de nuevos métodos diagnósticos y de seguimiento de la infección por schistosoma haematobium"
Referencia: PI23CIII00034 / MPY 386/23
Fecha Inicio: 01/01/2024
Fecha Fin: 31/12/2026
Financiación: 131.500 Euros
Investigador principal: Javier Sotillo
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)
Título del proyecto: "Desarrollo de herramientas para el control de la teniosis / cisticercosis en zonas endémicas y vigilancia de las helmintosis humanas emergentes en España"
Referencia: PI22CIII/00010
Fecha Inicio: 01/01/2023
Fecha Fin: 31/12/2025
Financiación: 80.000 Euros
Investigador principal: María Jesús Perteguer
Agencia Financiadora: Instituto de Salud Carlos III (ISCIII/AESI)
PROYECTOS PASADOS
Título del proyecto: "PERITAS: Molecular epidemiological studies on pathways of transmission and longlasting capacity building to prevent cystic echinococcosis infection."
Coordinador: Adriano Casulli. IP of ISCIII: Maria J. Perteguer.
Entidad financiadora: EULAC Health JOINT CALL on Research and Innovation 016-2017
Periodo: 01/03/2019-31/12/2022.
Cuantía total: 1.083.580 €.
Título del proyecto: "Producción de antígenos y controles positivos recombinantes para el desarrollo y la estandarización de nuevos ensayos serológicos aplicados al diagnóstico y control de helmintosis olvidadas. "
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 02/11/2018 - 31/06/2022.
Cuantía total: 78.050 €.
Título del proyecto: "Diagnóstico serológico diferencial de helmintiasis asociadas a eosinofilia: desarrollo de ensayos multianalito (xMAP) con antígenos recombinantes de especies de interés clínico"
Investigador principal: María Jesús Perteguer.
Entidad financiadora: ISCIII-AESI. Instituto de Salud Carlos III
Periodo: 01/01/2015 - 31/12/2018 .
Cuantía total: 91.000 €.
Publications
PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease
Ramos-Sevillano E, Urzainqui A, de Andrés B, González-Tajuelo R, Domenech M, González-Camacho F, Sánchez-Madrid F, Brown JS, García E, Yuste J. PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease. PLoS Pathog. 2016 Mar 14;12(3):e1005500. doi: 10.1371/journal.ppat.1005500. PMID: 26975045; PMCID: PMC4790886.
DOIComparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
Martínez-González E; Brochado-Kith O; Gómez-Sanz A; et al; Fernández-Rodríguez A (AC). (9/9). 2020. Small RNA sequencing from plasma extracellular vesicles of HIV/HCV coinfected patients: a protocol comparison SCIENTIFIC REPORTS. 9. ISSN 2045-2322.
DOIRelative telomere length impact on mortality of COVID-19: Sex differences
Virseda-Berdices A; Concostrina-Martinez L; Martínez-González O;et al; Fernández-Rodríguez A (AC). (14/14). 2022. Relative telomere length impact on mortality of COVID-19: Sex differences.Journal of medical virology. 95, pp.e28368. ISSN 0146-6615.
DOIHepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients
Martínez-Román P; López-Huertas MR; Crespo-Bermejo C; et al; Briz V (AC). (16/15). 2020. Hepatitis C virus influences HIV-1 viral splicing in coinfected patients JOURNAL OF CLINICAL MEDICINE. MDPI. ISSN 2077-0383.
DOIHCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
Brochado-Kith; Martínez I; Berenguer J; et al; Fernández-Rodríguez A (AC); Resino S. (11/12). 2021. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Sciences. Springer Nature. 28-1.
DOIOLFM4 polymorphisms predict septic shock survival after major surgery. Eur J Clin Invest.
Pérez-García F; Resino S; Gómez-Sánchez E; et al; Jiménez-Sousa MÁ (10/10). OLFM4 polymorphisms predict septic shock survival after major surgery. Eur J Clin Invest. 2021. 51(4):e13416. doi: 10.1111/eci.13416.
Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Buitrago MJ, Lopez JF, Grimalt JO, Cuenca-Estrella JM, Rodriguez-Tudela JL. Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother. 2006 Feb
Alcazar-Fuoli L, Mellado E, Garcia-Effron G, Buitrago MJ, Lopez JF, Grimalt JO, Cuenca-Estrella JM, Rodriguez-Tudela JL. Aspergillus fumigatus C-5 sterol desaturases Erg3A and Erg3B: role in sterol biosynthesis and antifungal drug susceptibility. Antimicrob Agents Chemother. 2006 Feb;50(2):453-60. doi: 10.1128/AAC.50.2.453-460.2006. PMID: 16436696; PMCID: PMC1366924.
PUBMED14. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008 Apr
Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008 Apr;52(4):1244-51. doi: 10.1128/AAC.00942-07. Epub 2008 Jan 22. PMID: 18212093; PMCID: PMC2292508.
PUBMED DOIAdditional Information
Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.
The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.
One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.
However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.
Our objectives are research into well-established autochthonous viruses (Toscana, West Nile and Lymphocoriomeningitis), imported viruses with a vector in Spain (mainly Zika, Dengue and Chikungunya), and viruses that cause haemorrhagic fevers (such as Ebola, Lassa or Crimea Congo, which despite being autochthonous, we include in this category) without forgetting other viruses that, at any time, may become emerging viruses and cause public health alerts.
The group's main research objective is to identify and characterise the aforementioned viruses that cause disease and those circulating in our environment with pathogenic potential.
One of the cross-cutting objectives of the laboratory is to optimise methods for the detection of these viruses and their application to determine the incidence, prevalence and/or presence of the viruses in our environment.
However, in addition to methodological development, it is important to know the origin of the circulating viruses, their antigenic relationships with related viruses, the pathogenicity of the different isolates or the interactions of the agents with their host both in cell culture and in arthropod vectors when this is possible. The aim is to strengthen our role as a National Reference Laboratory for zoonoses through research.